Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology® - A podcast by ReachMD
Categories:
Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr. Alan Bryce, who presented a session on this exact topic at the 2024 ASCO Genitourinary Cancers Symposium.
